Tags

Type your tag names separated by a space and hit enter

A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism.
Eur J Endocrinol. 2004 Mar; 150(3):351-4.EJ

Abstract

OBJECTIVE

To compare the clinical efficacy and safety of the combination of spironolactone (100 mg/day) plus finasteride (5 mg/day) and spironolactone (100 mg/day) alone in the treatment of hirsutism.

PATIENTS AND MEASUREMENTS

Sixty-five hirsute women were randomly assigned to one of these two treatment groups. Hirsutism score was measured according to the modified Ferriman-Gallwey scoring system. Baseline and post-treatment assessments were carried out in each subject by an investigator blinded to the therapy. Both groups had similar demographic properties at baseline. The serum levels of total and free testosterone, dehydroepiandrosterone sulphate and sex hormone-binding globulin were measured at the beginning and after 1 year of therapy. Blood chemistry and side-effects were evaluated during the study. Hirsutism scores were decreased significantly in both groups at the end of the year.

RESULTS

The mean percentage change in hirsutism scores from baseline in the spironolactone plus finasteride-treated group (51.3%) was significantly (P<0.005) higher than in the group treated with spironolactone alone (36.6%). Patients from both treatment groups experienced similar side-effects.

CONCLUSIONS

We have concluded that a combination of spironolactone plus finasteride is a safe and effective therapy in the treatment of hirsutism.

Authors+Show Affiliations

Department of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15012621

Citation

Keleştimur, Fahrettin, et al. "A Comparison Between Spironolactone and Spironolactone Plus Finasteride in the Treatment of Hirsutism." European Journal of Endocrinology, vol. 150, no. 3, 2004, pp. 351-4.
Keleştimur F, Everest H, Unlühizarci K, et al. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol. 2004;150(3):351-4.
Keleştimur, F., Everest, H., Unlühizarci, K., Bayram, F., & Sahin, Y. (2004). A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. European Journal of Endocrinology, 150(3), 351-4.
Keleştimur F, et al. A Comparison Between Spironolactone and Spironolactone Plus Finasteride in the Treatment of Hirsutism. Eur J Endocrinol. 2004;150(3):351-4. PubMed PMID: 15012621.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. AU - Keleştimur,Fahrettin, AU - Everest,Hatice, AU - Unlühizarci,Kürşad, AU - Bayram,Fahri, AU - Sahin,Yilmaz, PY - 2004/3/12/pubmed PY - 2004/5/5/medline PY - 2004/3/12/entrez SP - 351 EP - 4 JF - European journal of endocrinology JO - Eur J Endocrinol VL - 150 IS - 3 N2 - OBJECTIVE: To compare the clinical efficacy and safety of the combination of spironolactone (100 mg/day) plus finasteride (5 mg/day) and spironolactone (100 mg/day) alone in the treatment of hirsutism. PATIENTS AND MEASUREMENTS: Sixty-five hirsute women were randomly assigned to one of these two treatment groups. Hirsutism score was measured according to the modified Ferriman-Gallwey scoring system. Baseline and post-treatment assessments were carried out in each subject by an investigator blinded to the therapy. Both groups had similar demographic properties at baseline. The serum levels of total and free testosterone, dehydroepiandrosterone sulphate and sex hormone-binding globulin were measured at the beginning and after 1 year of therapy. Blood chemistry and side-effects were evaluated during the study. Hirsutism scores were decreased significantly in both groups at the end of the year. RESULTS: The mean percentage change in hirsutism scores from baseline in the spironolactone plus finasteride-treated group (51.3%) was significantly (P<0.005) higher than in the group treated with spironolactone alone (36.6%). Patients from both treatment groups experienced similar side-effects. CONCLUSIONS: We have concluded that a combination of spironolactone plus finasteride is a safe and effective therapy in the treatment of hirsutism. SN - 0804-4643 UR - https://www.unboundmedicine.com/medline/citation/15012621/A_comparison_between_spironolactone_and_spironolactone_plus_finasteride_in_the_treatment_of_hirsutism_ DB - PRIME DP - Unbound Medicine ER -